Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
常规交易时段
US$1.32
−US$0.11 · -7.69%
盘中时间采用ET。市场数据可能有所延迟。
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
日内区间
当前US$1.32
52周区间
当前US$1.32
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
46
合理估值
情绪
50
多空交织
风险
65
高风险
动量
22
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
日内区间
当前US$1.32
52周区间
当前US$1.32
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 851.8万 USD | — | — | — | — |
| 毛利 | −851.8万 USD | — | — | — | — |
| 研究与开发 | 36.82万 USD | 77万 USD | 717.37万 USD | 1583.68万 USD | 854.85万 USD |
| 销售、一般及管理费用 | 372.78万 USD | 496.43万 USD | 572.12万 USD | 713.84万 USD | 610.46万 USD |
| 营业费用 | 409.6万 USD | 573.43万 USD | 1289.49万 USD | 3184.11万 USD | 1281.29万 USD |
| 利息收入 | 9.55万 USD | 15.85万 USD | 35.23万 USD | 218.73 USD | — |
| 折旧和摊销 | 7151 USD | 4424 USD | 1.01万 USD | 6677 USD | 1.92万 USD |
| 营业利润 | −1261.4万 USD | −573.43万 USD | −1289.49万 USD | −3184.11万 USD | −1281.29万 USD |
| 净利润 | −1251.85万 USD | −557.58万 USD | −1254.27万 USD | −3160.8万 USD | −1276.82万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。